The Observational Health Data Sciences and Informatics (OHDSI) collaboration released a preprint entitled “Renin-angiotensin system blockers and susceptibility to COVID-19: a multinational open science cohort study.”
Preprints are preliminary reports of work that have not been certified by peer review. They should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information.
The preprint is available here.
There was no clear increased risk of COVID-19 diagnosis, hospitalization, or subsequent complications found for users of either angiotensin-converting enzyme inhibitors (ACEs) or angiotensin receptor blockers (ARBs) among a multinational cohort of more than 1.1 million patients using antihypertensives.
This study, the most comprehensive one to date of COVID-19 susceptibility risks for antihypertensive users, examined electronic health records from a trio of data sources from the United States and Spain (Columbia University Irving Medical Center, the Department of Veteran Affairs and SIDIAP) to conduct a systematic cohort study of ACE, ARB, calcium channel blocker (CCB) and thiazide diuretic (THZ) users.
“We currently lack reliable, transparent and generalizable evidence to inform antihypertensive choice in light of COVID-19,” says Dr. Marc Suchard, a professor at UCLA and research team leader. “This work strives to openly and reproducibly leverage real-world data to help.”
As a consequence, the study, powered by open-source tools and global collaboration within the OHDSI community, reinforces current clinical guidelines surrounding antihypertensive therapy. The findings indicate that patients should continue their ACE or ARB therapy, despite early concerns about potential risks.
Furthermore, the findings showed no clinical reason to switch from an ARB to ACE to minimize COVID-19 risk. “Based on our results, if there is a risk difference, it’s marginal and would be very challenging to further refine outside such a large-scale international study,” Dr. Suchard says.
The International COVID-ACE Receptor Inhibition Utilization and Safety (ICARIUS) protocol, code, and results are all available for further exploration at GitHub - ohdsi-studies/Covid19Icarius: Real-world, observational study to estimate the population-level effects of angiotensin converting enzyme (ACE) inhibitors and angiotensin II receptor blockers (ARB) on coronavirus disease (COVID-19) incidence and complications.
These are preliminary findings that are currently in the peer-review process. They should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information.
OHDSI is a multi-stakeholder, interdisciplinary collaborative to bring out the value of health data through large-scale analytics. All solutions are open-source. OHDSI has established an international network of researchers and observational health databases with a central coordinating center housed at Columbia University.
